Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas.

PubWeight™: 1.42‹?› | Rank: Top 5%

🔗 View Article (PMID 3585441)

Published in J Clin Oncol on June 01, 1987

Authors

E C Borden, D A Amato, C Rosenbaum, H T Enterline, M J Shiraki, R H Creech, H J Lerner, P P Carbone

Articles citing this

Advanced chondrosarcomas: role of chemotherapy and survival. Ann Oncol (2013) 1.08

An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs (2006) 1.08

Hepatic metastases from soft-tissue sarcoma. Ann Surg (1995) 0.96

Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches. Cancer (2011) 0.95

Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline. Sarcoma (2000) 0.95

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer (1998) 0.93

Chemotherapy for metastatic soft tissue sarcomas--another full circle? Br J Cancer (1991) 0.89

Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study. Eur J Cancer (2012) 0.87

Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results. Cancers (Basel) (2013) 0.87

Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas. Invest New Drugs (2000) 0.86

Anthracyclines: cardiotoxicity and its prevention. Arch Dis Child (1994) 0.85

Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma. Invest New Drugs (2009) 0.84

Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS). Invest New Drugs (2006) 0.84

Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group. Sarcoma (2000) 0.83

Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma. Sarcoma (2008) 0.82

An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. Invest New Drugs (2003) 0.81

Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study. Br J Cancer (2011) 0.81

Outcome analysis in patients with uterine sarcoma. Radiat Oncol J (2015) 0.80

Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol (2015) 0.78

High-Dose Chemotherapy Followed by Peripheral and/or Bone Marrow Stem Cell Transplant in Patients With Advanced Sarcoma: Experience of a Canadian Centre. Sarcoma (2004) 0.78

Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue Sarcomas. Sarcoma (2004) 0.78

Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival. Onco Targets Ther (2016) 0.77

Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study. Southwest Oncology Group. Invest New Drugs (2002) 0.77

Multimodality therapy for metastatic sarcomas confined to the lung. Oncol Lett (2012) 0.77

Bone metastases from bladder perivascular epithelioid cell tumor - an unusual localization of a rare tumor: a case report. J Med Case Rep (2014) 0.77

Treatment of Adult Soft Tissue Sarcomas: An Overview. Rare Cancers Ther (2015) 0.77

A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma. Invest New Drugs (2012) 0.77

Clinical efficacy of vorinostat in a patient with leiomyosarcoma. Clin Med Insights Oncol (2012) 0.75

Neoadjuvant sequential chemoradiotherapy versus radiotherapy alone for treatment of high-risk extremity soft tissue sarcoma: a single-institution experience. Contemp Oncol (Pozn) (2017) 0.75

Depletion of enteric bacteria diminishes leukocyte infiltration following doxorubicin-induced small intestinal damage in mice. PLoS One (2017) 0.75

Doxorubicin and Dacarbazine (AD) Regimen for Soft Tissue Sarcomas. Hosp Pharm (2015) 0.75

The role of adjuvant therapy in uterine leiomyosarcoma. Expert Rev Anticancer Ther (2015) 0.75

Patterns of care for patients with advanced soft tissue sarcoma: experience from Australian sarcoma services. Clin Sarcoma Res (2016) 0.75

Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther Adv Med Oncol (2017) 0.75

Managing sarcoma: where have we come from and where are we going? Ther Adv Med Oncol (2017) 0.75

Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. Invest New Drugs (2016) 0.75

Articles by these authors

Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (1982) 43.81

Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res (1971) 13.16

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med (1980) 6.12

Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore) (1970) 5.98

Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med (1970) 5.03

Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer (1977) 4.95

Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis (2003) 3.73

Assessment of response to therapy in advanced breast cancer. Br J Cancer (1977) 3.70

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med (1992) 3.54

A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer (1985) 2.82

The surgical management of patients with melanoma. Plast Reconstr Surg (1967) 2.62

Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci U S A (1996) 2.45

Hodgkin's disease. Immunologic, clinical, and histologic features of 50 untreated patients. Ann Intern Med (1967) 2.38

Ectopic production of human chorionic gonadotrophin by neoplasms. Ann Intern Med (1973) 2.30

Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ (2004) 2.17

Endomyocardial disease and eosinophilia. A clinical and pathologic spectrum. Am J Med (1969) 2.13

Human polyomavirus infections with JC virus and BK virus in renal transplant patients. Ann Intern Med (1980) 2.07

Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res (1998) 2.04

In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J Immunol (1996) 1.98

Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst (1990) 1.97

Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol (2001) 1.94

Intestinal lymphangiectasia: a protein-losing enteropathy with hypogammaglobulinemia, lymphocytopenia and impaired homograft rejection. J Clin Invest (1967) 1.88

Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res (1987) 1.87

Malignant "Triton" tumors. Natural history and immunohistochemistry of nine new cases with literature review. Cancer (1985) 1.84

Pseudomonas pneumonia. A retrospective study of 36 cases. Am J Med (1973) 1.83

Fundamental dilemmas of the randomized clinical trial process: results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators. J Clin Oncol (1994) 1.79

Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Physiocochemical and serological studies. J Gen Virol (1971) 1.78

Interferon-induced indoleamine 2,3-dioxygenase activity inhibits Chlamydia psittaci replication in human macrophages. J Interferon Res (1989) 1.74

Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res (2001) 1.73

Pseudohyperkalemia due to release of potassium from white blood cells during clotting. N Engl J Med (1966) 1.73

A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer (1978) 1.71

Primary gastric lymphomas. A clinicopathologic study of 58 cases with long-term follow-up and literature review. Cancer (1983) 1.70

Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J Interferon Res (1986) 1.70

Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol (1987) 1.65

Summary of infectious complications occurring in patients with Hodgkin's disease. Cancer Res (1966) 1.62

Recovery of cytomegalovirus from adults with neoplastic disease. Ann Intern Med (1966) 1.58

Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Electron microscopic studies. J Gen Virol (1971) 1.56

Single-void urine samples can be used to estimate quantitative microalbuminuria. Diabetes Care (1987) 1.54

Concepts of fever: recent advances and lingering dogma. Clin Infect Dis (1997) 1.50

Extrapulmonary small-cell carcinoma. A review of the literature with emphasis on therapy and outcome. Medicine (Baltimore) (1987) 1.50

A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma. J Immunol (1991) 1.47

Rapid detection and identification of JC virus and BK virus in human urine by using immunofluorescence microscopy. J Clin Microbiol (1980) 1.42

Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. J Leukoc Biol (1989) 1.41

Barrett's metaplasia and adenocarcinoma of the esophagus and gastroesophageal junction. Hum Pathol (1983) 1.40

Design considerations for AIDS trials. N Engl J Med (1990) 1.38

Pathologic analysis of advanced adult soft tissue sarcomas, bone sarcomas, and mesotheliomas. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer (1989) 1.38

Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med (1980) 1.37

The interferon refractory state: in vivo and in vitro studies of its mechanism. J Immunol (1971) 1.34

Infection in lymphoma. Histology, treatment, and duration in relation to incidence and survival. JAMA (1966) 1.34

Cancer treatment and age: patient perspectives. J Natl Cancer Inst (1993) 1.34

Special report. Steriod receptors in breast cancer. N Engl J Med (1979) 1.33

Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. Experientia (1989) 1.33

Enhancement of the antitumor effects of 1,3-bis(2-chloroethyl)-1-nitrosourea and cyclophosphamide by vitamin A. J Natl Cancer Inst (1972) 1.32

Chromosome constitution of adenoma and adenocarcinoma of the colon. Cancer (1967) 1.29

Treatment of Burkitt's tumor with cyclophosphamide. Cancer (1970) 1.29

Bacillus Calmette-Guerin in the treatment of neoplastic disease. J Reticuloendothel Soc (1974) 1.29

L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med (1969) 1.29

In vitro growth of normal and leukemic human bone marrow. J Natl Cancer Inst (1971) 1.27

Specific release of proteoglycans from human natural killer cells during target lysis. Nature (1985) 1.26

Clinical implications of cytogenetic variants in chronic myelocytic leukemia (CML). Blood (1968) 1.26

Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells. Cancer Res (1982) 1.25

Elevated antibody titers to Epstein-Barr virus in Hodgkin's disease. Cancer (1971) 1.25

Lobular carcinoma in situ of the breast. Long-term followup. Cancer (1974) 1.25

Plasmacytic myeloma. A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients. Am J Med (1967) 1.25

Beta interferon inhibits Toxoplasma gondii growth in human monocyte-derived macrophages. Infect Immun (1989) 1.20

"The state of the art" toward defining the role of radiation therapy in the management of small cell bronchogenic carcinoma. Int J Radiat Oncol Biol Phys (1980) 1.20

A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans. J Clin Invest (1990) 1.20

Lymphangiomyoma, a benign lesion of chyliferous lymphatics synonymous with lymphangiopericytoma. Cancer (1966) 1.17

Lobular carcinoma of the breast in situ and infiltrating. Pathol Annu (1976) 1.17

Management of patients with malignant lymphoma: a comparative study with cyclophosphamide and vinca alkaloids. Cancer Res (1968) 1.16

Central nervous system involvement in Burkitt's lymphoma. Blood (1970) 1.16

Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil. Cancer (1975) 1.16

The health consequences of smoking. Cancer. Med Clin North Am (1992) 1.15

Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer (1983) 1.14

Hematologic and cytogenetic remission of blastic transformation in chronic granulocytic leukemia. Blood (1971) 1.14

An overview of the interferon system: signal transduction and mechanisms of action. Cancer Invest (1996) 1.14

Streptovaricins inhibit focus formation by MSV (MLV) complex. Nat New Biol (1971) 1.14

Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer (2006) 1.13

Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland. Eur J Cancer (1978) 1.13

Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer (1978) 1.13

Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic patients with hemophilia. NHF-ACTG 036 Study Group. Blood (1991) 1.11

Long-term culture and characterization of human neurofibroma-derived Schwann cells. J Neurosci Res (2000) 1.11

A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol (1986) 1.11

A lesson from the mammography issue. Ann Intern Med (1978) 1.11

Lymphoma of the breast. Ann Surg (1981) 1.11

Activation of human natural killer cells cytotoxic for human leukemia cells by purified interferon. J Immunol (1979) 1.09

Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol (1991) 1.08

Squamous-cell carcinoma of the pilonidal sinus: report of a case and review of the literature. J Surg Oncol (1979) 1.08

Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J Clin Oncol (1987) 1.08

Survival of patients at Pennsylvania Hospital with hepatic metastases from carcinoma of the colon and rectum. Dis Colon Rectum (1972) 1.08

Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962. Cancer Res (1965) 1.08

Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer (1983) 1.07

Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer (1990) 1.07

Hodgkin's disease. Combined clinical staff conference at the National Institutes of Health. Ann Intern Med (1967) 1.07

Acetohydroxamate: bacterial urease inhibitor with therapeutic potential in hyperammonaemic states. Nature (1965) 1.07